PETALING JAYA: Duopharma Biotech Bhd’s net profit for the third quarter ended Sept 30, 2026 (Q3’26) rose 23.9% to RM27.98 million from RM22.57 million a year earlier, supported by improved product mix, lower input costs and operational efficiencies.

Revenue, however, declined 5.6% to RM210.05 million from RM222.49 million previously, mainly due to lower public sector insulin sales following the normalisation of demand after exceptional sales in the first half of 2025, according to a filing with Bursa Malaysia today.

The pharmaceutical group said stronger gross profit margins, improved manufacturing efficiencies and lower imported active pharmaceutical ingredient costs, amid a strengthening ringgit, supported its earnings growth.